Y. Saidi

发表

O222 Treatment interruption in children with chronic HIV-infection: the results of the paediatric European network for treatment of AIDS (PENTA) 11 trial

C. Giaquinto, F. Monpoux, D. Nadal, 2008 .

Late-onset neonatal sepsis: genetic differences by sex and involvement of the NOTCH pathway

Timothy H. Ciesielski, G. Sirugo, W. Scott, 2022, Pediatric Research.

Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future

M. Sandhu, O. Kirk, M. Rosińska, 2016 .

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

J. Seeley, C. Giaquinto, O. Kobusingye, 2021, BMC Infectious Diseases.

Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial

C. Giaquinto, A. Walker, J. Darbyshire, 2002, The Lancet.

A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: The PENTA-4 trial

C. Giaquinto, J. Darbyshire, D. Gibb, 1998 .

Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3–<36 months

C. Giaquinto, W. Snowden, Linda J Harrison, 2010, Antiviral therapy.

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children

D. Pillay, C. Giaquinto, A. Walker, 2007, AIDS.

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

M. Hughes, C. Giaquinto, L. Mofenson, 2011, The Lancet. Infectious diseases.

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Ana C. Matos, C. Königs, C. Giaquinto, 2022, The lancet. HIV.

HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds

Linda J Harrison, D. Gibb, R. McKinney, 2015, Journal of acquired immune deficiency syndromes.

Hepatic, Renal, Hematologic, and Inflammatory Markers in HIV-Infected Children on Long-term Suppressive Antiretroviral Therapy

Linda J Harrison, A. Turkova, M. Warshaw, 2017, Journal of the Pediatric Infectious Diseases Society.

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial

C. Giaquinto, N. Klein, T. Bunupuradah, 2016, The lancet. HIV.

Response to planned treatment interruptions in HIV infection varies across childhood

J. Ananworanich, J. Darbyshire, F. Monpoux, 2010, AIDS.

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Ana C. Matos, C. Königs, J. Seeley, 2022, The lancet. HIV.

Long‐term clinical, virological and immunological outcomes following planned treatment interruption in HIV‐infected children

C. Giaquinto, N. Klein, D. Gibb, 2020, HIV medicine.

Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.

S. Khoo, D. Gibb, T. Cressey, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Current management of late onset neonatal bacterial sepsis in five European countries

C. Giaquinto, V. Usonis, T. Metsvaht, 2014, European Journal of Pediatrics.

Adherence to Antiretroviral Therapy and Outcomes in HIV-Infected Patients Enrolled in An Induction/Maintenance Randomized Trial

F. Brun-Vézinet, F. Raffi, G. Peytavin, 2001, Antiviral therapy.

Estimating the proportion of treatment effect explained by a surrogate marker by D. Y. Lin, T. R. Fleming and V. De Gruttola, Statistics in Medicine, 16, 1515–1527 (1997)

P. Flandre, Y. Saidi, Y. Saîdi, 1999 .

Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial—ANRS HB02 VAC-ADN

D. Scott‐Algara, S. Pol, M. Bourgine, 2014, Gut.

Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinic

J. Blackstone, E. Williams, C. Giaquinto, 2023, EClinicalMedicine.